| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-05-11 |
详情>>
业绩披露：
2020年一季报每股收益-0.45美元,归母净利润-2129.35万美元,同比去年增长22.31%
|
| 2020-05-04 |
复牌提示：
2020-05-04 06:56:07 停牌，复牌日期 2020-05-04 07:30:00
|
| 2020-04-29 |
股东大会：
将于2020-06-25召开股东大会
会议内容 ▼▲
- 1.The election of three Class II directors, until their successors are elected and qualified;
2.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020;
3.Approval of an amendment to our 2016 Equity Incentive Plan to increase the number of authorized shares issuable by 2,500,000 shares;
4.The transaction of any other business that may properly come before the 2020 Annual Meeting or any adjournment of the 2020 Annual Meeting.
|
| 2020-04-29 |
详情>>
股本变动：
变动后总股本5247.28万股
|
| 2020-03-16 |
财报披露：
美东时间 2020-03-16 盘前发布财报
|
| 2020-03-16 |
详情>>
业绩披露：
2019年年报每股收益-1.83美元,归母净利润-7681.72万美元,同比去年增长9.65%
|
| 2019-11-12 |
详情>>
业绩披露：
2019年三季报(累计)每股收益-1.46美元,归母净利润-5913.72万美元,同比去年增长-1.28%
|
| 2019-08-06 |
详情>>
业绩披露：
2019年中报每股收益-1.14美元,归母净利润-4424.87万美元,同比去年增长-18.48%
|
| 2019-05-10 |
详情>>
业绩披露：
2019年一季报每股收益-0.73美元,归母净利润-2740.73万美元,同比去年增长-48.82%
|
| 2019-04-30 |
股东大会：
将于2019-06-25召开股东大会
会议内容 ▼▲
- 1.The election of two Class I directors, until their successors are elected and qualified;
2.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2019;
3.Approval of an amendment to our 2016 Equity Incentive Plan to increase the number of authorized shares issuable by 2,500,000 shares;
4.Approval of an amendment to our Certificate of Incorporation to increase our authorized share capital by 30,000,000 shares of common stock;
5.An advisory vote on the Company’s executive compensation as disclosed in the accompanying proxy statement;
6.An advisory vote on the frequency of the advisory vote on compensation of our named executive officers;
7.A stockholder proposal described in the Proxy Statement, if properly presented at the Annual Meeting;
8.The transaction of any other business that may properly come before the 2019 Annual Meeting or any adjournment of the 2019 Annual Meeting.
|
| 2019-03-15 |
详情>>
业绩披露：
2018年年报每股收益-2.99美元,归母净利润-8502.44万美元,同比去年增长-25.35%
|
| 2018-11-08 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-2.07美元,归母净利润-5838.95万美元,同比去年增长-26.72%
|
| 2018-09-12 |
详情>>
内部人交易：
Bergstein Ivan等共交易4笔
|
| 2018-08-09 |
详情>>
业绩披露：
2018年中报每股收益-1.34美元,归母净利润-3734.55万美元,同比去年增长-24.39%
|
| 2018-05-10 |
详情>>
业绩披露：
2018年一季报每股收益-0.69美元,归母净利润-1841.68万美元,同比去年增长-26.44%
|
| 2018-04-30 |
股东大会：
将于2018-06-21召开股东大会
会议内容 ▼▲
- 1.The election of two Class III directors, two Class II directors, and one Class I director, until their successors are elected and qualified;
2.The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018;
3.To approve an amendment to our 2016 Equity Incentive Plan to increase the number of authorized shares issuable by 2,900,000 shares;
4.The transaction of any other business that may properly come before the 2018 Annual Meeting or any adjournment of the 2018 Annual Meeting.
|
| 2018-03-16 |
详情>>
业绩披露：
2017年年报每股收益-2.94美元,归母净利润-6782.84万美元,同比去年增长-77.08%
|
| 2017-05-01 |
股东大会：
将于2017-06-19召开股东大会
会议内容 ▼▲
- 1. The election of two Class II directors until their successors are elected and qualified;
2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2017;
3. To approve an amendment to our 2016 Equity Incentive Plan to increase the number of authorized shares issuable by 1,200,000 shares;
4. To approve an amendment to our Certificate of Incorporation to increase our authorized share capital by 20,000,000 shares of common stock；
5. The transaction of any other business that may properly come before the 2017 Annual Meeting or any adjournment of the 2017 Annual Meeting.
|
| 2016-04-08 |
股东大会：
将于2016-05-25召开股东大会
会议内容 ▼▲
- 1. The election of one Class I director until his successor is elected and qualified;
2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2016;
3. The approval of our 2016 Long-Term Incentive Plan;
4. The transaction of any other business that may properly come before the 2016 Annual Meeting or any adjournment of the 2016 Annual Meeting.
|
| 2015-04-30 |
股东大会：
将于2015-06-23召开股东大会
会议内容 ▼▲
- 1. The election of two Class III directors and one Class I director until their respective successors are elected and qualified;
2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2015;
3. The approval of the Stemline Therapeutics, Inc. Employee Share Purchase Plan;
4. The transaction of any other business that may properly come before the 2015 Annual Meeting or any adjournment of the 2015 Annual Meeting.
|
| 2014-04-30 |
股东大会：
将于2014-06-19召开股东大会
会议内容 ▼▲
- 1. The election of two Class II directors until their respective successors are elected and qualified;
2. The ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2014;
3. The transaction of any other business that may properly come before the 2014 Annual Meeting or any adjournment of the 2014 Annual Meeting.
|